CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million. New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. Strategic acquisition under CBC's buyout strategy expected to drive significant value creation and positive patient outcomes through CBC's proven investor-operator approach and solution. SINGAPORE, Nov. 30, 2024 /PRNewswire/ -- CBC Group ("CBC"),
Nov. 30, 2024